421 related articles for article (PubMed ID: 12469362)
21. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
22. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Bellomo Damato A; Stefanelli G; Laviola L; Giorgino R; Giorgino F
Diabet Med; 2011 May; 28(5):560-6. PubMed ID: 21204958
[TBL] [Abstract][Full Text] [Related]
23. Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet.
Mine T; Miura K; Kajioka T; Kitahara Y
Metabolism; 2008 Jan; 57(1):140-8. PubMed ID: 18078871
[TBL] [Abstract][Full Text] [Related]
24. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
Intern Med; 2007; 46(22):1837-46. PubMed ID: 18025765
[TBL] [Abstract][Full Text] [Related]
25. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
26. Importance of postprandial glucose control.
Bell DS
South Med J; 2001 Aug; 94(8):804-9. PubMed ID: 11549192
[TBL] [Abstract][Full Text] [Related]
27. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
[TBL] [Abstract][Full Text] [Related]
28. Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.
Bell PM; Cuthbertson J; Patterson S; O'Harte FP
Diabetes Res Clin Pract; 2011 Mar; 91(3):e68-70. PubMed ID: 21194775
[TBL] [Abstract][Full Text] [Related]
29. Nateglinide, a new agent for postprandial glucose control in type 2 diabetes.
Kotapati S
Conn Med; 2002 May; 66(5):269-72. PubMed ID: 12071108
[No Abstract] [Full Text] [Related]
30. Effects of glibenclamide on postprandial coagulation activation.
Ioannidis I; Tsoukala C; Panayotopoulou C; Skrapari I; Maglara E; Anastasopoulou Y; Mandalaki T; Katsilambros N
Nutr Metab Cardiovasc Dis; 1999 Aug; 9(4):204-7. PubMed ID: 10614063
[TBL] [Abstract][Full Text] [Related]
31. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
[TBL] [Abstract][Full Text] [Related]
32. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
[TBL] [Abstract][Full Text] [Related]
33. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
[TBL] [Abstract][Full Text] [Related]
34. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
Kim MK; Suk JH; Kwon MJ; Chung HS; Yoon CS; Jun HJ; Ko JH; Kim TK; Lee SH; Oh MK; Rhee BD; Park JH
Diabetes Res Clin Pract; 2011 Jun; 92(3):322-8. PubMed ID: 21376417
[TBL] [Abstract][Full Text] [Related]
35. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
36. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Gribble FM; Manley SE; Levy JC
Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
[TBL] [Abstract][Full Text] [Related]
37. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man.
Raptis SA; Hatziagelaki E; Dimitriadis G; Draeger KE; Pfeiffer C; Raptis AE
Exp Clin Endocrinol Diabetes; 1999; 107(6):350-5. PubMed ID: 10543411
[TBL] [Abstract][Full Text] [Related]
38. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
[TBL] [Abstract][Full Text] [Related]
39. Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test.
Mori Y; Kuriyama G; Tajima N
Endocrine; 2004 Dec; 25(3):203-6. PubMed ID: 15758246
[TBL] [Abstract][Full Text] [Related]
40. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
O'Neal DN; O'Brien RC; Timmins KL; Grieve GD; Lau KP; Nicholson GC; Kotowicz MA; Best JD
Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
